Evidence map›Paper›PMID 40622541›Full record

ReviewAdvances in experimental medicine and biology2025

The C-Type Lectin Receptors.

Kasturi Ganguly, Taruna Madan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kasturi GangulyDepartment of Innate Immunity, Indian Council of Medical Research (ICMR)-National Institute for Research in Reproductive and Child Health (NIRRCH), Mumbai, India. guptat@nirrch.res.in.
Taruna MadanDivision of Development Research, Indian Council of Medical Research (ICMR), New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-type lectins (CTLs) form a broad and diverse protein superfamily with the ability to identify a wide array of ligands with their characteristic C-type lectin-like domains (CTLDs), thus governing a broad spectrum of physiological functions. CTLD-containing proteins (CTLDcps) are now classified into 17 groups based on their phylogeny and overall domain organization. While much research has centered on the role of C-type lectins in innate and adaptive antimicrobial immune responses, their significance extends further. They are increasingly acknowledged for their significant involvement in cancer biology. It has been evident that the CLR signaling can wield dual effects akin to a double-edged sword across various microbial or oncogenic scenarios. Consequently, the therapeutic potential of both agonists and antagonists targeting CLR signaling is now surfacing as innovative strategies. The growing body of evidence highlighting the indispensable role of C-type lectin receptors (CTLR) in numerous biological processes underscores the necessity for a deeper comprehension of their functional capabilities in both immune defense and disease contexts.

Indexed as

Immunity, InnateLectins, C-TypeNeoplasmsAdaptive ImmunityAnimalsHumansSignal TransductionLectins, C-TypeCancer immunologyCLRsCTLDInnate immunityMicrobial immunity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.